Cornercap Investment Counsel’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cornercap Investment Counsel’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,687	Closed	-$1.59M	–	661
2022 Q3	$1.59M	Buy	25,687 +3,419	+15%	+$239K	0.3%	85
2022 Q2	$1.78M	Buy	+22,268	New	+$2.11M	0.31%	82
2021 Q2	–	Sell	-14,053	Closed	-$1.29M	–	623
2021 Q1	$1.29M	Sell	14,053 -15,858	-53%	-$1.34M	0.14%	212
2020 Q4	$1.08M	Buy	29,911 +16,087	+116%	+$1.2M	0.15%	190
2020 Q3	$1.07M	Sell	13,824 -3,747	-21%	-$258K	0.15%	177
2020 Q2	$977K	Sell	17,571 -11,621	-40%	-$497K	0.16%	194
2020 Q1	$865K	Sell	29,192 -4,630	-14%	-$157K	0.17%	168
2019 Q4	$1.22M	Sell	33,822 -4,053	-11%	-$124K	0.17%	180
2019 Q3	$1.03M	Hold	37,875	–	–	0.15%	249
2019 Q2	$911K	Buy	+37,875	New	+$961K	0.12%	326

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cornercap Investment Counsel's HZNP Position: Q4 2022 in Review

Cornercap Investment Counsel sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 25,687 shares — an estimated $1.59M sold.

Cornercap Investment Counsel first reported a position in HZNP in Q2 2019 and held it in 10 quarters. The position peaked at $1.78M in Q2 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Cornercap Investment Counsel reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Cornercap Investment Counsel sold 25,687 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $1.59M.
Cornercap Investment Counsel first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 10 quarters.
Cornercap Investment Counsel's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.78M in Q2 2022.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Cornercap Investment Counsel's 13F filing for Q4 2022, filed 13 Feb 2023.